百利天恒与百时美施贵宝就iza-bren的全球战略合作协议触发里程碑付款条件

Core Viewpoint - The company SystImmune, Inc., a wholly-owned subsidiary of Baillie Tianheng, has entered into an exclusive licensing and collaboration agreement with Bristol-Myers Squibb for the drug iza-bren (BL-B01D1, EGFR×HER3 dual antibody ADC) [1] Group 1 - The recent milestone in the global Phase II/III pivotal registration clinical trial IZABRIGHT-Breast01 has triggered the first payment of $250 million under the collaboration agreement [1] - SystImmune is expected to receive the payment shortly, with the actual amount subject to bank fees [1] - Under the collaboration agreement, Baillie Tianheng is eligible for up to an additional $250 million in near-term contingent payments, as well as up to $7.1 billion in further payments upon achieving specific development, registration, and sales milestones [1]